Invivoscribe | Personalized Molecular Medicine

Notice: Acute Myeloid Leukemia (AML) The FDA has made it clear that a FLT3 companion diagnostic is required for approval of any FLT3-targeted or FLT3-stratified therapy. LabPMM is the only clinical laboratory with access to the patents required to develop and offer a FLT3 companion diagnostic for worldwide use(excluding Japan).

Personalized Medicine & IVS
Invivoscribe is a leading provider of clinically-validated CE-marked in vitro diagnostic products. Through our subsidiary, LabPMM, we provide worldwide access to molecular biomarker testing, which enables pharmaceutical companies to bring to the market new targeted treatments, and allows physicians to better determine optimal treatment for their patients.

Research & Biotechnology
Development & Partnering
Companion Diagnostics

LabPMM and New York

LabPMM is proud to announce that we have received our New York state clinical lab license. We expect to start accepting samples from New York patients within 30 days. Please contact us with any questions.

Invivoscribe Launches the LymphoTrack™ DeepSeq™ TCRG Assay - MiSeq

This Next Generation Sequencing (NGS) assay provides data for the study of TCRG clonality and provides the frequency distribution and DNA sequence of rearranged TCRG V-J sequences using the MiSeq platform. Click here for more information. Contact us to learn more.

Invivoscribe Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire Clinically-Actionable Genetic Menu.

Click here to learn more about Genection.

CE-marked TCRG Gene Rearrangement Assay 2.0

This in vitro diagnostic assay, which is available for sale and use only outside North America, detects the vast majority of clonal T cell receptor gamma gene rearrangements with a single multiplex master mix, generates a single Gaussian distribution in a size range consistent with testing FFPE specimens, and comes with software that assists with objective interpretation. Contact us or visit our online catalog to learn more.

TCRG Gene Rearrangement Assay 2.0

Our improved assay detects the vast majority of clonal T cell receptor gamma gene rearrangements with a single multiplex master mix, and generates a single Gaussian distribution in a size range consistent with testing FFPE specimens. Contact us or visit our online catalog to learn more.

BCR/ABL Lyophilized Cell Controls and RNA Dilution Sets are available

We have released our BCR/ABL b3a2, b2a2, and e1a2 Lyophilized Cell Controls and RNA Dilution Sets.

In the News

May 14, 2013 Marketwire
Invivoscribe Prevails in German District Court (FLT3 Patent Infringement Action)

December 5, 2012 Marketwire
Takara Bio Grants Patent License to Invivoscribe Technologies for FLT3-ITD Testing in Japan

December 4, 2012 Marketwire
Invivoscribe Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire Clinically-Actionable Genetic Test Menu

May 15, 2012 USPTO
United States Patent No. 8,178,292 issued on May 15, 2012. This patent further consolidates our already dominant intellectual property around the detection of FLT3-ITD mutations

December 26, 2011 The New York Times
A Push to Tie New Drugs to Testing by Andrew Pollack

February 23, 2011 Pharmacogenomics Reporter
Novartis, Invivoscribe to Develop Companion Test for Acute Myeloid Leukemia Rx Midostaurin

February 21, 2011 BioCentury
Invivoscribe Technologies Inc., Novartis deal

Press Releases
February 15, 2011
Invivoscribe Announces Collaboration Agreement to Develop Companion Diagnostic

Our growth continues... and continues...

We doubled space at our San Diego headquarters in 2011, building out two additional suites for cGMP manufacturing and shipping. In April 2012 we expanded into another adjacent suite to secure offices for management personnel. LabPMM LLC expanded into dedicated space San Diego in 2011, and LabPMM GmbH, located in Martinsried, Germany, started the move into our brand new European reference laboratory in September 2011. Personnel were hired and completed training at our San Diego facility, and we anticipate completion of assay validation and the start of clinical testing in 2Q2012.

View all News